Compass Therapeutics (CMPX) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Compass Therapeutics (CMPX) over the past year, losing 46.3% versus a loss of 71.7%. Over five years, TARA leads with a -62.1% price change compared with -68.2% for CMPX. Compass Therapeutics is the larger company by market cap ($183.7 million vs $153.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | TARA |
|---|---|---|
| Share price | $1.02 | $2.59 |
| Market cap | $183.69M | $153.06M |
| 1-day change | +2.19% | +1.37% |
| YTD return | -81.01% | -51.41% |
| 1-year return | -71.75% | -46.27% |
| 5-year return | -68.22% | -62.13% |
| EPS (TTM) | $-0.39 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $7.82 |
| 52-week low | $0.829 | $2.51 |
| Distance from 52-week high | -85.17% | -66.88% |
| Average volume | 4.08M | 801.43K |
| Shares outstanding | 180.09M | 59.10M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARA has outperformed CMPX by 25.5 percentage points over the past year.
CMPX vs TARA FAQ
Which is bigger, Compass Therapeutics or Protara Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $183.69M compared with $153.06M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, CMPX or TARA?
TARA returned -46.27% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.